Tasman Therapeutics
PrivateLast Round
Series A
Apr 3, 2025
Total Funding Raised
$175M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Tasman Therapeutics is a clinical-stage pharmaceutical company developing innovative treatments for neuropsychiatric disorders, including its lead product candidate R-107, an extended-release oral ketamine tablet for treatment-resistant depression.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Mental Health, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tasman Therapeutics Comparables
Compare Tasman Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neurocentrx Pharma | 91% | |
| HMNC Brain Health | 89% | |
| MIRA Pharmaceuticals, Inc. | 80% |
Tasman Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 3, 2025 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 169% MoM.
- Apr 3, 2025
$175M round completed.
Recent news
Latest coverage and updates
- partners_withAug 12, 2026
Tasman Therapeutics Incorporated partnered with Osmind on Aug 12th '26.
Tasman Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Tasman Therapeutics's valuation, stock price, and market status.
Is Tasman Therapeutics a public or private company?
Tasman Therapeutics is a private company.
What is the current stock price of Tasman Therapeutics?
Tasman Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Tasman Therapeutics worth (valuation)?
Valuation information for Tasman Therapeutics is not publicly available.
Can I buy Tasman Therapeutics stock?
Tasman Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Tasman Therapeutics's last funding round?
Tasman Therapeutics's most recent funding round was Series A on April 3, 2025.
Who are the main investors in Tasman Therapeutics?
Investor information for Tasman Therapeutics is not publicly disclosed.
Will Tasman Therapeutics IPO soon?
No public IPO plans have been announced for Tasman Therapeutics.
How can I track Tasman Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Tasman Therapeutics's secondary market activity and sign up for updates.